These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

252 related articles for article (PubMed ID: 18804135)

  • 1. Production, quality control, stability and pharmacotoxicity of cGMP-produced Plasmodium falciparum AMA1 FVO strain ectodomain expressed in Pichia pastoris.
    Faber BW; Remarque EJ; Kocken CH; Cheront P; Cingolani D; Xhonneux F; Jurado M; Haumont M; Jepsen S; Leroy O; Thomas AW
    Vaccine; 2008 Nov; 26(48):6143-50. PubMed ID: 18804135
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Production, Quality Control, Stability and Pharmacotoxicity of a Malaria Vaccine Comprising Three Highly Similar PfAMA1 Protein Molecules to Overcome Antigenic Variation.
    Faber BW; Hellwig S; Houard S; Havelange N; Drossard J; Mertens H; Croon A; Kastilan R; Byrne R; van der Werff N; van der Eijk M; Thomas AW; Kocken CH; Remarque EJ
    PLoS One; 2016; 11(10):e0164053. PubMed ID: 27695087
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Phase 1 randomized controlled trial to evaluate the safety and immunogenicity of recombinant Pichia pastoris-expressed Plasmodium falciparum apical membrane antigen 1 (PfAMA1-FVO [25-545]) in healthy Malian adults in Bandiagara.
    Thera MA; Coulibaly D; Kone AK; Guindo AB; Traore K; Sall AH; Diarra I; Daou M; Traore IM; Tolo Y; Sissoko M; Niangaly A; Arama C; Baby M; Kouriba B; Sissoko MS; Sagara I; Toure OB; Dolo A; Diallo DA; Remarque E; Chilengi R; Noor R; Sesay S; Thomas A; Kocken CH; Faber BW; Imoukhuede EB; Leroy O; Doumbo OK
    Malar J; 2016 Aug; 15(1):442. PubMed ID: 27577237
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Immunogenicity of a recombinant malaria vaccine candidate, domain I+II of AMA-1 ectodomain, from Indian P. falciparum alleles.
    Lalitha PV; Biswas S; Pillai CR; Saxena RK
    Vaccine; 2008 Aug; 26(35):4526-35. PubMed ID: 18590786
    [TBL] [Abstract][Full Text] [Related]  

  • 5. High-level production and purification of P30P2MSP1(19), an important vaccine antigen for malaria, expressed in the methylotropic yeast Pichia pastoris.
    Brady CP; Shimp RL; Miles AP; Whitmore M; Stowers AW
    Protein Expr Purif; 2001 Dec; 23(3):468-75. PubMed ID: 11722185
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Immune responses in mice induced by prime-boost schemes of the Plasmodium falciparum apical membrane antigen 1 (PfAMA1)-based DNA, protein and recombinant modified vaccinia Ankara vaccines.
    Miao J; Li X; Liu Z; Xue C; Bujard H; Cui L
    Vaccine; 2006 Sep; 24(37-39):6187-98. PubMed ID: 16806600
    [TBL] [Abstract][Full Text] [Related]  

  • 7. posttranslational modification of recombinant Plasmodium falciparum apical membrane antigen 1: impact on functional immune responses to a malaria vaccine candidate.
    Giersing B; Miura K; Shimp R; Wang J; Zhou H; Orcutt A; Stowers A; Saul A; Miller LH; Long C; Singh S
    Infect Immun; 2005 Jul; 73(7):3963-70. PubMed ID: 15972483
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Fermentation, purification, and efficacy of a recombinant vaccine candidate against botulinum neurotoxin type F from Pichia pastoris.
    Byrne MP; Titball RW; Holley J; Smith LA
    Protein Expr Purif; 2000 Apr; 18(3):327-37. PubMed ID: 10733887
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Optimization of a multi-stage, multi-subunit malaria vaccine candidate for the production in Pichia pastoris by the identification and removal of protease cleavage sites.
    Spiegel H; Schinkel H; Kastilan R; Dahm P; Boes A; Scheuermayer M; Chudobová I; Maskus D; Fendel R; Schillberg S; Reimann A; Fischer R
    Biotechnol Bioeng; 2015 Apr; 112(4):659-67. PubMed ID: 25335451
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Overproduction of Pichia pastoris or Plasmodium falciparum protein disulfide isomerase affects expression, folding and O-linked glycosylation of a malaria vaccine candidate expressed in P. pastoris.
    Tsai CW; Duggan PF; Shimp RL; Miller LH; Narum DL
    J Biotechnol; 2006 Feb; 121(4):458-70. PubMed ID: 16274825
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Evaluation of three Pichia pastoris-expressed Plasmodium falciparum merozoite proteins as a combination vaccine against infection with blood-stage parasites.
    Zhang D; Pan W
    Infect Immun; 2005 Oct; 73(10):6530-6. PubMed ID: 16177327
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Detailed functional characterization of glycosylated and nonglycosylated variants of malaria vaccine candidate PfAMA1 produced in Nicotiana benthamiana and analysis of growth inhibitory responses in rabbits.
    Boes A; Spiegel H; Edgue G; Kapelski S; Scheuermayer M; Fendel R; Remarque E; Altmann F; Maresch D; Reimann A; Pradel G; Schillberg S; Fischer R
    Plant Biotechnol J; 2015 Feb; 13(2):222-34. PubMed ID: 25236489
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Functional analysis of Plasmodium falciparum apical membrane antigen 1 utilizing interspecies domains.
    Healer J; Triglia T; Hodder AN; Gemmill AW; Cowman AF
    Infect Immun; 2005 Apr; 73(4):2444-51. PubMed ID: 15784590
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A diversity-covering approach to immunization with Plasmodium falciparum apical membrane antigen 1 induces broader allelic recognition and growth inhibition responses in rabbits.
    Remarque EJ; Faber BW; Kocken CH; Thomas AW
    Infect Immun; 2008 Jun; 76(6):2660-70. PubMed ID: 18378635
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Purification, characterization, and immunogenicity of the refolded ectodomain of the Plasmodium falciparum apical membrane antigen 1 expressed in Escherichia coli.
    Dutta S; Lalitha PV; Ware LA; Barbosa A; Moch JK; Vassell MA; Fileta BB; Kitov S; Kolodny N; Heppner DG; Haynes JD; Lanar DE
    Infect Immun; 2002 Jun; 70(6):3101-10. PubMed ID: 12011004
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Construction and evaluation of a multistage combination vaccine against malaria.
    Zhang Q; Xue X; Qu L; Pan W
    Vaccine; 2007 Mar; 25(11):2112-9. PubMed ID: 17241708
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Malaria vaccine-related benefits of a single protein comprising Plasmodium falciparum apical membrane antigen 1 domains I and II fused to a modified form of the 19-kilodalton C-terminal fragment of merozoite surface protein 1.
    Faber BW; Remarque EJ; Morgan WD; Kocken CH; Holder AA; Thomas AW
    Infect Immun; 2007 Dec; 75(12):5947-55. PubMed ID: 17938224
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Enhanced expression of a recombinant malaria candidate vaccine in Escherichia coli by codon optimization.
    Zhou Z; Schnake P; Xiao L; Lal AA
    Protein Expr Purif; 2004 Mar; 34(1):87-94. PubMed ID: 14766303
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Scale-up of the fermentation and purification of the recombinant heavy chain fragment C of botulinum neurotoxin serotype F, expressed in Pichia pastoris.
    Johnson SK; Zhang W; Smith LA; Hywood-Potter KJ; Todd Swanson S; Schlegel VL; Meagher MM
    Protein Expr Purif; 2003 Nov; 32(1):1-9. PubMed ID: 14680933
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Production and purification of the heavy-chain fragment C of botulinum neurotoxin, serotype B, expressed in the methylotrophic yeast Pichia pastoris.
    Potter KJ; Bevins MA; Vassilieva EV; Chiruvolu VR; Smith T; Smith LA; Meagher MM
    Protein Expr Purif; 1998 Aug; 13(3):357-65. PubMed ID: 9693060
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.